Kidswell Bio Corporation (TYO:4584)
Japan · Delayed Price · Currency is JPY 134.00
+1.00 (0.75%)
Jun 24, 2026, 3:30 PM JST
Kidswell Bio Income Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | Mar '20 Mar 31, 2020 |
Operating Revenue | 6,590 | 4,718 | 1,569 | 996 | 1,077 |
Other Revenue | - | 364 | - | - | - |
| 6,590 | 5,082 | 1,569 | 996 | 1,077 | |
Revenue Growth (YoY) | 29.67% | 223.90% | 57.53% | -7.52% | 5.41% |
Cost of Revenue | 5,192 | 3,649 | 551 | 120 | 654 |
Gross Profit | 1,398 | 1,433 | 1,018 | 876 | 423 |
Selling, General & Admin | 541.94 | 638 | 787 | 883 | 687 |
Research & Development | 1,120 | 767 | 1,150 | 963 | 898 |
Operating Expenses | 1,662 | 1,405 | 1,937 | 1,846 | 1,585 |
Operating Income | -263.78 | 28 | -919 | -970 | -1,162 |
Interest Expense | -49.06 | -42 | -15 | -15 | -5 |
Interest & Investment Income | 5.08 | - | - | - | - |
Currency Exchange Gain (Loss) | -2.82 | -2 | -9 | -3 | -1 |
Other Non Operating Income (Expenses) | -64.34 | 17 | -11 | -5 | -19 |
EBT Excluding Unusual Items | -374.92 | 1 | -954 | -993 | -1,187 |
Gain (Loss) on Sale of Investments | -15.8 | 35 | 417 | -7 | -145 |
Gain (Loss) on Sale of Assets | - | 4 | 2 | 1 | - |
Asset Writedown | -1.05 | -6 | - | -1 | -5,982 |
Other Unusual Items | -11.17 | 39 | 1 | - | - |
Pretax Income | -402.93 | 73 | -534 | -1,000 | -7,314 |
Income Tax Expense | 11.07 | 94 | 1 | 1 | 2 |
Net Income | -413.99 | -21 | -535 | -1,001 | -7,316 |
Net Income to Common | -413.99 | -21 | -535 | -1,001 | -7,316 |
Shares Outstanding (Basic) | 50 | 41 | 31 | 29 | 28 |
Shares Outstanding (Diluted) | 50 | 41 | 31 | 29 | 28 |
Shares Change (YoY) | 22.47% | 31.28% | 7.16% | 4.14% | 41.55% |
EPS (Basic) | -8.35 | -0.52 | -17.34 | -34.77 | -264.64 |
EPS (Diluted) | -8.35 | -0.52 | -17.34 | -34.77 | -264.64 |
Free Cash Flow | -1,111 | 930 | -1,169 | -1,267 | -1,326 |
Free Cash Flow Per Share | -22.39 | 22.96 | -37.89 | -44.01 | -47.97 |
Gross Margin | 21.22% | 28.20% | 64.88% | 87.95% | 39.28% |
Operating Margin | -4.00% | 0.55% | -58.57% | -97.39% | -107.89% |
Profit Margin | -6.28% | -0.41% | -34.10% | -100.50% | -679.29% |
Free Cash Flow Margin | -16.86% | 18.30% | -74.51% | -127.21% | -123.12% |
EBITDA | -263.53 | - | -917 | - | -1,162 |
EBITDA Margin | -4.00% | - | -58.45% | - | -107.86% |
D&A For EBITDA | 0.25 | - | 2 | - | 0.32 |
EBIT | -263.78 | 28 | -919 | -970 | -1,162 |
EBIT Margin | -4.00% | 0.55% | -58.57% | -97.39% | -107.89% |
Effective Tax Rate | - | 128.77% | - | - | - |
Revenue as Reported | 6,590 | - | - | - | - |